SandipPravinPatelMDProfessor(He/Him)

Oncology • La Jolla, CA

Hematologic Oncology, Thoracic Cancer, Clinical Informatics

Leader, Experimental Therapeutics Deputy Director, San Diego Center for Precision Immunotherap

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
3855 Health Sciences Drive
La Jolla, CA 92093
Phone+1 858-822-6580

Fax+1 858-822-6186

Summary

Early phase clinical trials of cancer immunotherapy, solid tumor cellular therapy, thoracic immunooncology, spatial immune profiling, irAEs

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2008 - 2011
Baylor College of MedicineClass of 2008
Duke UniversityBA, Political Science, Magna Cum Laude, 2000 - 2004

Certifications & Licensure

CA State Medical License 2009 - 2027
NC State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Commendation for Excellence in Medical Student Teaching 2008 - 2009, 2009
“Most Awards” Award 2008 - 2009, 2009
Dean’s List 2000 - 2001, 2000 - 2002, 2002
Dean’s List w/t Distinction 2002
Killson Educational Foundation Scholarship
Phi Beta Kappa National Academic Honor Society
Pi Sigma Alpha National Political Science Honor Society
Goldwater Scholarship semifinalist for Duke University
National Merit Scholarship Winner, National Advanced Placement Scholar with Distinction High School
National Qualifier for Quiz Bowl, Fourth place at national TEAMS engineering contest, State Qualifier for Debate
Join now to see all

Clinical Trials

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01
Completed
Phase 1, Phase 2
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Start of enrollment: 2016 Apr 14
Completed
Phase 1, Phase 2
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2016 May 09
Terminated
Phase 2
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Start of enrollment: 2017 Jan 30
Active, not recruiting
Phase 2
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed Start of enrollment: 2018 Apr 05
Terminated
Phase 1
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Start of enrollment: 2018 Aug 29
Completed
Phase 1, Phase 2
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Start of enrollment: 2018 Dec 27
Active, not recruiting
Phase 1
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Apr 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radia...
Zachary S Zumsteg, Siddharth Sheth, Salma K Jabbour, Krishnan R Patel, Randall J Kimple
The Lancet. Oncology. 2024-10-01
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers, Chung-Tsen Hsueh
Journal for Immunotherapy of Cancer. 2024-09-28
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Narjust Florez, Sandip P Patel, Heather Wakelee, Lyudmila Bazhenova, Erminia Massarelli
The Oncologist. 2024-09-05

Abstracts/Posters

Photocrosslinkable Polymers for Biomedical Applications.
Grinstaff MW, Carnahan PS, Fleming DL, Hatchell NR, Luman MT, Patel SP, 222nd American Chemical Society
Abstract #896 appears in Blood, Volume 106, issue 11.
Travel grant recipient and poster presentation, American Society of Hematology Conference 2005
Empiric treatment as a means of diagnosis in AIDS patients with CNS lesions.
Poster Presentation, Society of General Internal Medicine Conference 2009

Lectures

SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Tempus Announces the Clinical Launch of Its Immune Profile Score Algorithmic TestNovember 7th, 2024
Early-Stage Non-Small Lung CancerAugust 28th, 2024
FDA Approvals Create “Difficult Decisions” in Early-Stage Resectable NSCLCAugust 26th, 2024
Join now to see all